What's the Problem?

Among birth defects, heart disease is the leading cause of death globally. Currently, there are more than 70 million people worldwide living with diseases that affect the heart's aortic valve. While adults have the option of valve replacement, the situation becomes dire for children due to the scarcity of therapeutic alternatives. As children get older, any implanted valves gradually become smaller. Sadly, a substantial proportion of these young patients succumb to heart failure.

How are they Solving it?

AVaTAR is a medical device designed to construct a customized aortic or pulmonary valve using the patient's own tissue, allowing for a fast, simple, and safe implantation process. With more than 20 years of experience in pediatric cardiology and cardiovascular surgery, we embarked on the development of this device by initiating a proof-of-concept stage, which involved performing various mathematical calculations. Subsequently, we performed extensive computational simulations within a 3D modeling laboratory and proceeded to evaluate the functionality of the valve both in vitro and in vivo, using a porcine model. Rigorous testing consistently demonstrated the exceptional performance of the valve in all evaluations conducted. This success allowed us to validate our device during operations on real patients. To date, we have successfully performed 17 surgeries with the device, replacing 11 aortic valves and 6 pulmonary valves in children.

Go to their website

Next Startup

Alytix

Go back to portfolio